Cargando…

TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease

Alpha-synuclein (α-Syn) accumulation/aggregation and mitochondrial dysfunction play prominent roles in the pathology of Parkinson’s disease. We have previously shown that postmortem human dopaminergic neurons from PD brains accumulate high levels of mitochondrial DNA (mtDNA) deletions. We now addres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bender, Andreas, Desplats, Paula, Spencer, Brian, Rockenstein, Edward, Adame, Anthony, Elstner, Matthias, Laub, Christoph, Mueller, Sarina, Koob, Andrew O., Mante, Michael, Pham, Emily, Klopstock, Thomas, Masliah, Eliezer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633917/ https://www.ncbi.nlm.nih.gov/pubmed/23626796 http://dx.doi.org/10.1371/journal.pone.0062277

Ejemplares similares

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
por: Kim, Changyoun, et al.
Publicado: (2015)

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
por: Spencer, Brian, et al.
Publicado: (2015)

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies
por: Price, Diana L., et al.
Publicado: (2016)

α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
por: Spencer, Brian, et al.
Publicado: (2016)

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2017)

Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2020)

Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease
por: Desplats, Paula, et al.
Publicado: (2012)

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
por: Spencer, Brian, et al.
Publicado: (2017)

Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
por: Iba, Michiyo, et al.
Publicado: (2020)

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
por: Overk, Cassia R, et al.
Publicado: (2014)

ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
por: Spencer, Brian, et al.
Publicado: (2014)

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity
por: Fields, Jerel A., et al.
Publicado: (2016)

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
por: Kim, Changyoun, et al.
Publicado: (2018)

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease
por: Valera, Elvira, et al.
Publicado: (2015)

Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
por: Kim, Changyoun, et al.
Publicado: (2021)

Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy
por: Crews, Leslie, et al.
Publicado: (2010)

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
por: Masliah, Eliezer, et al.
Publicado: (2011)

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
por: Mandler, Markus, et al.
Publicado: (2015)

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies
por: Hassen, Getaw Worku, et al.
Publicado: (2018)

Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions
por: Elstner, Matthias, et al.
Publicado: (2011)

S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson’s disease
por: Sunico, Carmen R, et al.
Publicado: (2013)

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
por: Amschl, David, et al.
Publicado: (2013)

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer
por: Fields, Jerel, et al.
Publicado: (2013)

A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick’s Disease and Fronto-Temporal Tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
por: Price, Diana L., et al.
Publicado: (2018)

Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease
por: Fang, Fang, et al.
Publicado: (2017)

Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases
por: Tsigelny, Igor F., et al.
Publicado: (2008)

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
por: Bae, Eun-Jin, et al.
Publicado: (2018)

The Temporal Expression Pattern of Alpha-Synuclein Modulates Olfactory Neurogenesis in Transgenic Mice
por: Schreglmann, Sebastian R., et al.
Publicado: (2015)

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
por: Rockenstein, Edward, et al.
Publicado: (2014)

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model
por: Xu, Jiqing, et al.
Publicado: (2016)

Biogenesis of Tom40, Core Component of the Tom Complex of Mitochondria
por: Rapaport, Doron, et al.
Publicado: (1999)

Therapeutic Potential of α-Synuclein Evolvability for Autosomal Recessive Parkinson's Disease
por: Wei, Jianshe, et al.
Publicado: (2021)

In Vivo Imaging of α-Synuclein in Mouse Cortex Demonstrates Stable Expression and Differential Subcellular Compartment Mobility
por: Unni, Vivek K., et al.
Publicado: (2010)

Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H ß-synuclein
por: Sekigawa, Akio, et al.
Publicado: (2012)

Oral N-Acetyl-Cysteine Attenuates Loss of Dopaminergic Terminals in α-Synuclein Overexpressing Mice
por: Clark, Joanne, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_m0d2ofs4f9d9uqgg85e71fo7r0